Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

5-AMINOSALICYLIC ACID

All products: general benefit

Other products in the same Health Canada class (A07E, A07EC) — coverage varies; not interchangeable

  • Mesalazine (Octasa): general benefit
  • Olsalazine (Dipentum): general benefit
  • Budesonide (Uceris): general benefit

Mezera · DIN 02474018 · 1g · suppository

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02474018 Manufacturer: Avir Pharma Inc.; listing date 2019-08-30 Health Canada: Marketed since 2018-07-13 · brand MEZERA · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1 G · company Avir pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Mezera: Formulary list price $1.9076/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.9076 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96402 · Verify on the e-Formulary ↗ (DIN 02474018)

Source record
DIN 02474018: Mezera Raw flags: sec3=Y Item: 564000136; group id 672; item number 1677; lccId None; manufacturer id AVP Source form: Sup; strength: 1g Recorded listing: General benefit Source prices (unrounded): $1.9076; ministry $1.9076 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474018 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96402
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

OLSALAZINE SODIUM

· 1 products · General benefit · strengths: 250mg · Cap

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

DOMPERIDONE MALEATE

· 11 products · Listed, not a benefit (1), General benefit (10) · strengths: 10mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

LACTULOSE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 667mg/mL · O/L

METOCLOPRAMIDE HCL

· 8 products · Limited Use, codes 481, 657 (2), Listed, not a benefit (2), General benefit (4) · strengths: 5mg/mL, 5mg, 10mg · Inj Sol (Preservative Free), Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications PENTASA (mesalazine) extended-release tablets are indicated for: • Treatment of mild to moderate active ulcerative colitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease. • Management of mild to moderate Crohn’s Disease and maintenance of Crohn’s Disease in remission induced by surgery or medication PENTASA (mesalazine) rectal suspension is indicated for: • Treatment of acute distal ulcerative colitis extending to the splenic flexure and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease. Clinical experience has shown that topical PENTASA (i.e. enemas/suppositories) is superior to oral PENTASA (i.e. tablets) with regard to therapeutic efficacy in distal ulcerative colitis (Table 3 - Clinical experience from pivotal trials). PENTASA (mesalazine) suppositories are indicated for: • Treatment of acute ulcerative proctitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of a… https://pdf.hres.ca/dpd_pm/00084316.PDF PM date: 2026-04-16 Source product: PENTASA; DIN 02099683; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.